BMJ (Clinical research ed.)|2025|Mahase E|6 citations
PMID: 40908029
14102 studies
We present the case of a 66-year-old woman who developed weakness, nausea, and vomiting accompanied by markedly elevated creatine kinase levels after first treatment with an increased dose of tirzepatide. Laboratory findings were consistent with rhab…
SUMMARY: Hypercalcemia is a prevalent electrolyte disturbance commonly associated with primary hyperparathyroidism, cancer, or medication adverse effects. Thiazide diuretics reduce urinary calcium excretion, increasing calcium reabsorption and hyperc…
OBJECTIVE: SURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD. METHODS:…
AIM: To evaluate the long-term efficacy and safety data at 104 weeks in tirzepatide-treated participants with type 2 diabetes who had inadequate glycaemic control on metformin and/or sulfonylurea. MATERIALS AND METHODS: This post-hoc analysis was bas…
[This corrects the article DOI: 10.3389/fendo.2025.1593134.].
The synthesis of tirzepatide relies heavily on solid phase peptide synthesis (SPPS), a process that is both costly and time-consuming. In this paper, a novel soluble liquid-phase assisted (LPPS) strategy for the efficient synthesis of tirzepatide is…
PURPOSE OF REVIEW: Little is known about how incretins interact with sleep and circadian factors, both of which influence metabolic outcomes. We review evidence that sleep, circadian rhythms, and their disturbances impact incretin secretion and discu…
The α-ketoacid-hydroxylamine (KAHA) ligation enables the chemoselective coupling of unprotected peptide segments. The most commonly used hydroxylamine building block, ()-5-oxaproline, yields homoserine residues at ligation sites, limiting application…
The global prevalence of early-onset type 2 diabetes (EOT2D) is rising rapidly. Adults with EOT2D represent a high-risk population characterised by increased rates of microvascular and macrovascular complications, adverse psychological wellbeing and…
BACKGROUND: Repurposing glucagon-like peptide-1 (GLP-1) and GIP/GLP-1 receptor agonists (RAs) for idiopathic intracranial hypertension (IIH) represents an attractive alternative to current treatments, supported by evidence of potent metabolic effects…
BACKGROUND: Prescription of obesity medications is increasing, but our understanding of their effects in patients with cardiovascular disorders, such as postural orthostatic tachycardia syndrome (POTS), is limited. CASE SUMMARY: POTS was exacerbated…
INTRODUCTION: Tirzepatide (TZP), a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, has been showing superior benefits in weight loss and glucose lowering in patients with obesity, while the tissue-specific…
AIMS: This post hoc analysis assessed the efficacy and safety data in tirzepatide-treated Korean patients with type 2 diabetes (T2D). MATERIALS AND METHODS: Data specifically from Korean patients treated with tirzepatide 5, 10, or 15 mg in the multic…